Acute Pain / Migraine

The reference markets are the migraine market and the non opioids market for treatment of Acute Pain. Migraine is characterized by recurring attacks of headache, often associated with visual, auditory or gastrointestinal disturbances. Triptans are the family of drugs most commonly prescribed for the treatment of migraine attacks. MS Health's IMS National Sales PerspectiveTM, or IMS, in 2007 total Triptans sales in the U.S. were approximately $2.3 billion.

APR has developed two different patented and innovative oral drug delivery technology:

One named Dynamic Buffering Technology or DBT which enhances the absorption of its active ingredient, Diclofenac potassium. By utilizing bicarbonate, DBT enables Diclofenac to enter the bloodstream at a faster rate of absorption and increased peak plasma concentrations.

The second is the proprietary RapidFilm™ technology which is a novel, non-mucoadhesive, fast dissolving oral dosage form based on a water soluble polymer. Placed on top of the tongue, the film disperses within seconds (water is not needed), promoting a gastrointestinal absorption comparable to immediate release oral solid dosage forms

Starting from those innovative technologies has been development a complete range of products for the migraine treatment, with products like Diclofenac K 50 mg powder comparable to the best effective current golden standard in this category (Triptans) or Diclofenac K 50 mg Tablets a unique pain reliever, that's the fastest oral diclofenac on the market.